Oruka Therapeutics annual operating cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oruka Therapeutics Operating Cash Flow Growth & History (ORKA)
Oruka Therapeutics's operating cash flow was −$88.2M for fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$88.2M | −$30.4M | — |
| 2024 | 2024-12-31 | −$57.8M | −$52.8M | — |
| 2023 | 2023-12-31 | −$5.0M | $5.9M | — |
| 2022 | 2022-12-31 | −$10.9M | $7.8M | — |
| 2021 | 2021-12-31 | −$18.8M | −$11.0M | — |
| 2020 | 2020-12-31 | −$7.7M | −$2.9M | — |
| 2019 | 2019-12-31 | −$4.8M | $3.4M | — |
| 2018 | 2018-12-31 | −$8.2M | $9.2M | — |
| 2017 | 2017-12-31 | −$17.5M | −$2.5M | — |
| 2016 | 2016-12-31 | −$15.0M | −$4.5M | — |
| 2015 | 2015-12-31 | −$10.5M | −$1.1M | — |
| 2014 | 2014-12-31 | −$9.4M | −$4.1M | — |
| 2013 | 2013-12-31 | −$5.3M | −$1.2M | — |
| 2012 | 2012-12-31 | −$4.1M | $2.9M | — |
| 2011 | 2011-12-31 | −$7.0M | $1.4M | — |
| 2010 | 2010-12-31 | −$8.3M | — | — |
Oruka Therapeutics quarterly operating cash flow
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$33.1M | −$10.0M | — |
| Q1 2026 | 2026-03-31 | −$23.6M | −$2.7M | — |
| Q4 2025 | 2025-12-31 | −$22.6M | — | — |
| Q3 2025 | 2025-09-30 | −$21.6M | $6.2M | — |
| Q2 2025 | 2025-06-30 | −$23.1M | — | — |
| Q1 2025 | 2025-03-31 | −$20.9M | −$19.3M | — |
| Q3 2024 | 2024-09-30 | −$27.8M | −$26.1M | — |
| Q1 2024 | 2024-03-31 | −$1.5M | $67,000 | — |
| Q4 2023 | 2023-12-31 | −$1.1M | $438,000 | — |
| Q3 2023 | 2023-09-30 | −$1.7M | $829,000 | — |
| Q2 2023 | 2023-06-30 | −$694,000 | $1.9M | — |
| Q1 2023 | 2023-03-31 | −$1.6M | $2.7M | — |
| Q4 2022 | 2022-12-31 | −$1.5M | $3.5M | — |
| Q3 2022 | 2022-09-30 | −$2.5M | $2.4M | — |
| Q2 2022 | 2022-06-30 | −$2.6M | $1.1M | — |
| Q1 2022 | 2022-03-31 | −$4.3M | $927,000 | — |
| Q4 2021 | 2021-12-31 | −$4.9M | −$2.0M | — |
| Q3 2021 | 2021-09-30 | −$4.9M | −$2.9M | — |
| Q2 2021 | 2021-06-30 | −$3.7M | −$2.7M | — |
| Q1 2021 | 2021-03-31 | −$5.2M | −$3.5M | — |
| Q4 2020 | 2020-12-31 | −$3.0M | −$1.8M | — |
| Q3 2020 | 2020-09-30 | −$2.0M | −$1.1M | — |
| Q2 2020 | 2020-06-30 | −$1.0M | $148,000 | — |
| Q1 2020 | 2020-03-31 | −$1.7M | −$120,000 | — |
| Q4 2019 | 2019-12-31 | −$1.2M | $185,000 | — |
| Q3 2019 | 2019-09-30 | −$887,000 | $689,000 | — |
| Q2 2019 | 2019-06-30 | −$1.2M | $1.1M | — |
| Q1 2019 | 2019-03-31 | −$1.6M | $1.5M | — |
| Q4 2018 | 2018-12-31 | −$1.3M | $2.9M | — |
| Q3 2018 | 2018-09-30 | −$1.6M | $2.4M | — |
| Q2 2018 | 2018-06-30 | −$2.3M | $2.7M | — |
| Q1 2018 | 2018-03-31 | −$3.1M | $1.3M | — |
| Q4 2017 | 2017-12-31 | −$4.2M | −$354,000 | — |
| Q3 2017 | 2017-09-30 | −$4.0M | −$238,000 | — |
| Q2 2017 | 2017-06-30 | −$5.0M | −$1.4M | — |
| Q1 2017 | 2017-03-31 | −$4.3M | −$461,000 | — |
| Q4 2016 | 2016-12-31 | −$3.8M | −$1.2M | — |
| Q3 2016 | 2016-09-30 | −$3.7M | −$1.3M | — |
| Q2 2016 | 2016-06-30 | −$3.5M | −$1.1M | — |
| Q1 2016 | 2016-03-31 | −$3.9M | −$770,000 | — |
| Q4 2015 | 2015-12-31 | −$2.6M | −$741,000 | — |
| Q3 2015 | 2015-09-30 | −$2.4M | −$325,000 | — |
| Q2 2015 | 2015-06-30 | −$2.4M | −$636,000 | — |
| Q1 2015 | 2015-03-31 | −$3.1M | $574,000 | — |
| Q4 2014 | 2014-12-31 | −$1.9M | −$7,000 | — |
| Q3 2014 | 2014-09-30 | −$2.1M | −$401,000 | — |
| Q2 2014 | 2014-06-30 | −$1.8M | −$787,000 | — |
| Q1 2014 | 2014-03-31 | −$3.7M | −$2.9M | — |
| Q4 2013 | 2013-12-31 | −$1.9M | −$1.2M | — |
| Q3 2013 | 2013-09-30 | −$1.7M | −$901,000 | — |
| Q2 2013 | 2013-06-30 | −$976,000 | $1,000 | — |
| Q1 2013 | 2013-03-31 | −$764,000 | $892,000 | — |
| Q4 2012 | 2012-12-31 | −$670,000 | $566,000 | — |
| Q3 2012 | 2012-09-30 | −$775,000 | $901,000 | — |
| Q2 2012 | 2012-06-30 | −$977,000 | $1.1M | — |
| Q1 2012 | 2012-03-31 | −$1.7M | $284,000 | — |
| Q4 2011 | 2011-12-31 | −$1.2M | — | — |
| Q3 2011 | 2011-09-30 | −$1.7M | $336,000 | — |
| Q2 2011 | 2011-06-30 | −$2.1M | — | — |
| Q1 2011 | 2011-03-31 | −$1.9M | — | — |
| Q3 2010 | 2010-09-30 | −$2.0M | — | — |
Oruka Therapeutics operating cash flow trends
Over the last five fiscal years, Oruka Therapeutics's operating cash flow decreased from −$7.7M to −$88.2M, a change of −$80.5M. The latest reported quarter, Q2 2026, shows −$33.1M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗Community posts
Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipien ...
